Apollo Hospitals Enterprise reported a 21% year-on-year rise in consolidated revenue to Rs 7,043 crore for the first quarter of FY27. EBITDA for the same period increased by 28% to Rs 1,092 crore, as the company prepares for the demerger of its digital health and pharmacy business.
Apollo Hospitals Enterprise posted strong financial results for the first quarter of the fiscal year 2027. The company's consolidated revenue grew 21% year-on-year, reaching Rs 7,043 crore. Operating profit, measured as EBITDA, also showed healthy growth, rising 28% compared to the same period last year to hit Rs 1,092 crore.
Alongside the financial performance, the company has declared a final dividend of Rs 10 per share for the financial year ending 2026, with the record date set for August 14, 2026. These updates come as investors track the company's progress on its strategic restructuring.
Management continues to work toward the planned demerger of the Apollo HealthCo business, which includes its omnichannel pharmacy and digital health services. The goal is to create an independently listed entity to focus on these consumer-centric healthcare segments, with expectations for the process to conclude by the fourth quarter of FY27.
While the company has shown growth in its core hospital business, there are specific factors for investors to monitor. The integration of new hospital beds and the time it takes for these new facilities to reach full operational capacity can affect short-term margins. Additionally, the process of demerging the pharmacy and digital health platform involves complex execution steps.
Profitability in the healthcare platform segments—specifically digital services and diagnostics—remains a key area to track. The company's ability to meet breakeven timelines for these newer segments will be a significant indicator of future financial health. Investors also keep an eye on regulatory changes and pressure on pricing in the healthcare sector, which can impact profitability across the industry.